Kyowa Kirin Co Ltd banner

Company Overview

Business Description

Sector
Health Care
Industry
Pharmaceuticals
Headquarters
Japan JP
Employees
5 161
IPO date
Aug 22, 1949

Kyowa Kirin is a Japanese pharmaceutical company that develops, makes, and sells prescription medicines. Its main business is creating drugs for serious conditions such as blood disorders, kidney-related diseases, and rare diseases, then bringing those medicines to hospitals and specialists who treat those patients. It also works on research and development, which is the starting point for its future drug pipeline.

The company sells medicines to healthcare providers and medical institutions, and in some cases partners with other drug companies to develop or commercialize treatments. Its money mainly comes from drug sales, plus licensing or collaboration income when it shares rights to certain products or technologies. Because drug development takes years and requires heavy scientific expertise, Kyowa Kirin’s role is less about mass-market consumer sales and more about supplying specialized treatments to doctors and patients with complex medical needs.

What makes its business model distinct is its focus on niche therapeutic areas where deep medical knowledge matters more than scale alone. Instead of trying to sell a broad range of common medicines, it concentrates on targeted therapies for hard-to-treat diseases, which can create long-lasting relationships with specialists and healthcare systems. That makes Kyowa Kirin a specialized drug maker rather than a general healthcare company.

Kyowa Kirin Co Ltd Investor Relations

Address
17F, Otemachi Financial City Grand Cube, 1-9-2, Ote-machi
Chiyoda-ku, Tokyo-To
Japan

Business Segments

Japan medicines

This unit sells Kyowa Kirin’s prescription medicines in Japan, including treatments for specialty diseases used in hospitals and clinics.

Customers and revenue model

North America medicines

This unit markets and sells the company’s medicines in the United States and Canada, with a focus on specialty treatments.

Customers and revenue model

EMEA medicines

Description, customers and revenue model

Asia Oceania medicines

Description, customers and revenue model

Management

Mr. Masashi Miyamoto Ph.D.

President, CEO & Representative Director

Biography unavailable

Mr. Motohiko Kawaguchi

CFO & Managing Executive Officer

Biography unavailable

Mr. Yutaka Osawa M.B.A.

CCO, Executive VP & Representative Director

Biography unavailable

Kazuki Nemoto

Head of Global Legal

Biography unavailable

Hiroki Nakamura

Global Corporate Communications Head

Biography unavailable

Hiroshi Sonekawa

Managing Executive Officer, VP and Head of Sales & Marketing Division

Biography unavailable

Shoko Itagaki

Executive Officer & Chief People Officer

Biography unavailable

Mr. Takeyoshi Yamashita Ph.D.

Chief Medical Officer, Senior Managing Executive Officer & Director

Biography unavailable

Yasuo Fujii M.B.A.

Chief Strategy Officer, VP & Managing Executive Officer

Biography unavailable

Jean-David Rafizadeh-Kabe J.D., M.D.

Head of Global Operational Transformation

Biography unavailable

1 / 10